
Opinion|Videos|May 28, 2025
Navigating the Heterogeneous Progression of Duchenne Muscular Dystrophy
Author(s)Diana Castro, MD
Duchenne Muscular Dystrophy progresses with motor delays, varying deterioration rates, and impacts multiple organs, highlighting the need for early intervention.
Advertisement
Episodes in this series

Summary for Physicians
Disease Progression in Duchenne Muscular Dystrophy (DMD)DMD
DMD progresses in stages, with initial motor milestone delays and a gradual loss of motor function. Key points include the following:
- Early delays in motor milestones like such as standing, walking, running, and climbing stairs.
- Maximum motor capacity typically achieved by age 6.5½, followed by a noticeable decline in function. Some children may lose the ability to walk as early as age 7 to -8 years, while others may progress more slowly.
- Wide range of progression: Some mutations (e.g.eg, those amenable to Eexon 44 skipping) may result in slower progression and less severe weakness.
- Dystrophin deficiency leads to muscle cell damage and affects multiple organs, including the heart, lungs, and digestive system, contributing to the disease's progressive nature.
- Respiratory and cardiac involvement develop with age, and early death was common before the use of steroids and other therapies.
- Prognosis improvement: With steroids and new therapies, life expectancy has increased, and newborn screening may further improve outcomes by enabling earlier interventions.
Advertisement
Related to this article

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

The director of the Center for Neurological Restoration at Cleveland Clinic discusses when to transition beyond oral medication and considerations for selecting device-aided therapies in PD.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients
2
Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy
3
The Road Ahead for Precision Medicine in Multiple Sclerosis
4
NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis
5




